S. Hermann

发表

Combined p53/Bax mutation results in extremely poor prognosis in gastric carcinoma with low microsatellite instability

B. Dörken, S. Hauptmann, A. Mrózek, 2003, Cell Death and Differentiation.

Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy

B. Dörken, P. Daniel, I. Sturm, 2003, Cell Death and Differentiation.

[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].

W. Hiddemann, C. Pott, S. Hermann, 2002, Deutsche medizinische Wochenschrift.

Bax expression in benign and malignant thyroid tumours: Dysregulation of wild‐type P53 is associated with a high Bax and P21 expression in thyroid carcinoma

B. Dörken, S. Hauptmann, A. Mrózek, 2001, International journal of cancer.

anemia Individualized risks of first adverse events in patients with Fanconi

W. Hiddemann, P. Rosenberg, C. Pott, 2010 .

Analysis of p53/BAX in primary colorectal carcinoma: Low BAX protein expression is a negative prognostic factor in UICC stage III tumors

H. Stein, B. Dörken, M. Zeitz, 2002, International journal of cancer.

Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome.

W. Hiddemann, C. Pott, M. Dreyling, 2000, Blood.

Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis

B. Dörken, S. Hauptmann, V. Budach, 2003, International journal of cancer.

Clinical Observations, Interventions, and Therapeutic Trials

C. Pott, M. Dreyling, S. Hermann, 2000 .